Alnylam Pharmaceuticals (ALNY) Gross Margin (2018 - 2026)

Alnylam Pharmaceuticals has reported Gross Margin for 9 years, with the latest figure at 82.22% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin rose 21616.0% year-over-year to 82.22%; the trailing twelve-month figure through Mar 2026 stood at 81.0% (down 94.0% YoY), and the FY2025 full-year result was 81.77%, down 460.0% from the prior year.
• Gross Margin for Q1 2026 stood at 82.22%, up from 75.6% in the prior quarter.
• The five-year high for Gross Margin was 89.8% in Q2 2024, with the low at 133.94% in Q1 2025.
• Historically, Gross Margin has averaged 71.62% across 5 years, with a median of 84.21% in 2025.
• Annual changes were most pronounced in 2025 — Gross Margin plunged 22290 bps — and 2026, when it jumped 21616 bps.
• Alnylam Pharmaceuticals' Gross Margin stood at 86.22% in 2022, then declined by 3 bps to 83.63% in 2023, then decreased by 1 bps to 82.69% in 2024, then declined by 9 bps to 75.6% in 2025, then climbed by 9 bps to 82.22% in 2026.
• The last three Gross Margin figures came in at 82.22% (Q1 2026), 75.6% (Q4 2025), and 84.21% (Q3 2025), per Business Quant data.